PT-141

The Complete Guide to Dosage, Benefits, and Research

1. PT-141 Dosage Chart | Quick Breakdown

PurposeDosageFrequencyAdministration
HSDD Treatment1.75 mgAs needed, max 8 times/monthSubcutaneous injection
ED Research1-4 mgAs neededSubcutaneous injection
General Research0.5-2 mgAs per protocolSubcutaneous injection

2. What is PT-141?

PT-141 also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Key points:

  • Chemical formula: C50H68N14O10
  • Molecular weight: 1025.2 g/mol
  • Developed from Melanotan II
  • FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women
  • Being studied for potential use in erectile dysfunction (ED)

3. PT-141 Mechanism of Action

PT-141 works through several mechanisms:

  • 1 Binds to and activates melanocortin receptors, particularly MC3R and MC4R
  • 2 Stimulates dopamine release in the central nervous system
  • 3 Affects neural pathways involved in sexual arousal and desire
  • 4 Potentially influences blood flow to genital tissues
  • 5 May modulate the hypothalamic-pituitary-gonadal axis
  • 6 Activates neurons in the medial preoptic area of the hypothalamus

4. Research Applications and Potential Benefits of PT-141

PT-141 and Hypoactive Sexual Desire Disorder (HSDD)

  • increases sexual desire in premenopausal women with HSDD
  • Improves sexual satisfaction and reduces distress related to low sexual desire

PT-141 and Erectile Dysfunction (ED)

  • Potential alternative treatment for men with ED
  • May be effective in cases where PDE5 inhibitors fail

PT-141 and Sexual Arousal

  • Enhances sexual arousal in both men and women
  • Potential treatment for generalized arousal disorders

PT-141 and Melanocortin System Research

  • Tool for studying melanocortin receptor functions
  • Insights into neural pathways involved in sexual behavior and motivation

5. PT-141 Dosage Guide

Dosing PT-141 for HSDD Treatment

  • FDA-approved dose: 1.75 mg
  • Administered subcutaneously at least 45 minutes before anticipated sexual activity
  • Maximum of 8 doses per month

Dosing PT-141 for ED Research

  • Typical dose range: 1-4 mg
  • Administered as needed, 45 minutes to 2 hours before sexual activity

Dosing PT-141 for General Research

  • Dose range: 0.5-2 mg
  • Frequency depends on specific research protocol

6. How to Mix and Administer PT-141

  • 1 Reconstitute lyophilized PT-141 with bacteriostatic water
  • 2 Use sterile injection materials
  • 3 Calculate dosage based on concentration (e.g., 10 mg/ml)
  • 4 Draw correct amount into insulin syringe
  • 5 Administer via subcutaneous injection

7. PT-141 Administration Methods

Subcutaneous Injection

  • Common injection sites: abdomen (2 inches away from navel), thigh, or upper arm
  • Inject into fatty tissue of abdomen or thigh

Nasal Spray

  • Less common, experimental method
  • May have lower bioavailability compared to injection

8. PT-141 Combinations and Interactions

PT-141 + PDE5 Inhibitors

  • Potential synergistic effects for ED treatment
  • Caution advised due to possible blood pressure effects

PT-141 + Alcohol

  • No significant interactions reported
  • Moderate alcohol consumption does not appear to affect PT-141 efficacy

Always consult a healthcare professional before combining medications.

9. Where to Buy PT-141 Online | 2024 Edition

PT-141 is a prescription medication for HSDD. For research purposes, it's crucial to source from reputable suppliers that provide certificates of analysis and third-party testing results.

10. Is PT-141 Safe?

Generally considered safe when used as directed, but potential side effects include:

  • Nausea (39.9-40.4%)
  • Facial flushing (20.4-20.6%)
  • Headaches (11-12%)
  • Mild serum enzyme elevations
  • Rare cases of acute liver injury

Long-term safety data beyond 52 weeks is limited.

11. Is PT-141 Legal?

  • FDA-approved for HSDD treatment in premenopausal women
  • Prescription-only medication in the United States
  • Legal status may vary in other countries
  • Research use should comply with local regulations

12. PT-141 Storage and Handling

  • Store lyophilized powder at room temperature (20-25°C or 68-77°F)
  • Once reconstituted, store in refrigerator (2-8°C or 36-46°F)
  • Use within 30 days after reconstitution
  • Protect from light and excessive heat
  • Always use sterile techniques when handling

13. Frequently Asked Questions (FAQ)

How quickly does PT-141 work?
Can PT-141 be used by men for ED?
How does PT-141 differ from Viagra or Cialis?
Are there any contraindications for PT-141 use?

14. PT-141 Dosage | Final Verdict

PT-141 (Bremelanotide) represents a novel approach to treating sexual dysfunction, particularly HSDD in premenopausal women. Its unique mechanism of action, targeting melanocortin receptors in the brain, offers potential benefits for those who may not respond to traditional treatments. The FDA-approved dosage of 1.75 mg administered subcutaneously as needed (up to 8 times per month) has shown efficacy in clinical trials.However, as with any medication, PT-141 should be used under medical supervision, and patients should be aware of potential side effects, particularly nausea and headaches. While promising for HSDD treatment, more research is needed to fully establish its efficacy and safety profile for other applications, such as male ED. As research continues, our understanding of PT-141's full potential and optimal use may evolve.

Table of Contents

1. PT-141 Dosage Chart | Quick Breakdown

2. What is PT-141?

3. PT-141 Mechanism of Action

4. Research Applications and Potential Benefits of PT-141

5. PT-141 Dosage Guide

6. How to Mix and Administer PT-141

7. PT-141 Administration Methods

8. PT-141 Combinations and Interactions

9. Where to Buy PT-141 Online | 2024 Edition

10. Is PT-141 Safe?

11. Is PT-141 Legal?

12. PT-141 Storage and Handling

13. Frequently Asked Questions (FAQ)

14. PT-141 Dosage | Final Verdict

15. References

15. References

  • 1 Kingsberg SA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 134(5), 899-908.
  • 2 Clayton AH, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health, 12(3), 325-337.
  • 3 Safarinejad MR. (2008). Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. The Journal of Sexual Medicine, 5(4), 887-897.
  • 4 Molinoff PB, et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102.
  • 5 FDA. (2019). FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. [Press Release]